PBA
IMCR icon

Paradigm Biocapital Advisors’s Immunocore IMCR Stock Holding History

Paradigm Biocapital Advisors’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,787,176
Closed -$116M – 41
2024
Q1 		$116M Buy
1,787,176
+333,293
+23% +$22.9M 4.09% 7
2023
Q4 		$99.3M Buy
1,453,883
+69,197
+5% +$3.6M 4.65% 8
2023
Q3 		$71.9M Buy
1,384,686
+114,562
+9% +$6.78M 4.88% 8
2023
Q2 		$76.2M Buy
1,270,124
+143,868
+13% +$8.21M 5.88% 3
2023
Q1 		$55.7M Buy
1,126,256
+268,331
+31% +$15.1M 5.28% 6
2022
Q4 		$49M Buy
857,925
+84,846
+11% +$4.78M 5.75% 8
2022
Q3 		$36.3M Buy
773,079
+105,662
+16% +$5.04M 4.84% 8
2022
Q2 		$24.9M Buy
667,417
+168,227
+34% +$5.46M 4.97% 9
2022
Q1 		$14.9M Buy
499,190
+364,941
+272% +$9.21M 3.95% 10
2021
Q4 		$4.6M Buy
+134,249
New +$4.86M 1.31% 22

Other funds holding IMCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Paradigm Biocapital Advisors's IMCR Position: Q2 2024 in Review

Paradigm Biocapital Advisors sold out of Immunocore (IMCR) in Q2 2024, closing a stake of 1,787,176 shares — an estimated $116M sold.

Paradigm Biocapital Advisors first reported a position in IMCR in Q4 2021 and held it in 10 quarters. The position peaked at $116M in Q1 2024. 138 funds tracked by Wall St. Rank hold IMCR as of Q2 2024.

  • Paradigm Biocapital Advisors reported no remaining Immunocore position as of Q2 2024 after selling out during the quarter.
  • Paradigm Biocapital Advisors sold 1,787,176 Immunocore shares in Q2 2024, an estimated $116M.
  • Paradigm Biocapital Advisors first reported a position in Immunocore in Q4 2021 and held it in 10 quarters.
  • Paradigm Biocapital Advisors's Immunocore position peaked at $116M in Q1 2024.
  • 138 funds tracked by Wall St. Rank held Immunocore as of Q2 2024.

Based on Paradigm Biocapital Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.